Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $17.68 USD
Change Today -0.14 / -0.79%
Volume 781.4K
HALO On Other Exchanges
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

11388 Sorrento Valley Road

San Diego, CA 92121

United States

Phone: 858-794-8889

Fax: 858-704-8311

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in making molecules into medicines for patients in need. The company’s research focuses primarily on human enzymes that alter the extracellular matrix. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. The company’s proprietary enzymes can be used to facilitate the delivery of injected drugs and fluids. The company’s proprietary pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. Strategy Key aspects of the company’s strategy include gaining approval for and launch its proprietary product candidates; maximizing royalty revenue from existing collaborations; and expanding and deepen collaborations. Product and Product Candidates The company has one marketed proprietary product and multiple proprietary product candidates targeting various indications in various stages of development. Proprietary Pipeline Hylenex Recombinant (hyaluronidase human injection) Hylenex recombinant is a formulation of rHuPH20 that has received the U.S. Food and Drug Administration (FDA) approval to facilitate subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. The company is continuing to assess its commercial and strategic options for the product to address additional uses, such as in connection with insulin pumps under Ultrafast Insulin Program. The majority of its approved product and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA) - a naturally occurring substance that is a major component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. Ultrafast Insulin Program The company’s most advanced proprietary program combines rHuPH20 with prandial (mealtime) insulin intended for the diabetes market. The company is viewing two distinct opportunities to enter the prandial insulin market: The first opportunity (what it refers to as the Continuous Subcutaneous Insulin Injection (CSII) market) is to pre-treat the insulin infusion site with Hylenex recombinant at the time of infusion site change (once every 3 days). The second opportunity (what it refers to as the Multiple Daily Injection (MDI) market) is to combine rHuPH20 with an FDA approved rapid acting analog insulin, such as insulin lispro (Humalog) (Lispro-PH20), insulin aspart (Novolog) (Aspart-PH20) and insulin glulisine (Apidra) (Glulisine-PH20), (each such combination, analog-PH20), to accelerate their action. PEGPH20 The company is developing PEGPH20, a new molecular entity, as a candidate for the systemic treatment of tumors that accumulate HA. In 2013, the company presented the results from a Phase 1b clinical study of PEGPH20 in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer (Phase 1b PEGPH20 Clinical Study). In 2013, the company initiated a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. HTI-501 HTI-501, an engineered drug formulation variant of cathepsin L (a lysosomal proteinase), that acts by degrading collagen, is the company’s primary conditionally-active biologic. The company is exploring HTI-501 as an approach to the treatment of edematous fibrosclerotic panniculopathy, also known as cellulite. Collaborations The company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter) and Intrexon Corporation (Intrexon), with two products approved for marketing in Europe, one product candidate, which has been submitted for regulatory approval in the U.S., one product candidate which has been submitted for regulatory a

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $17.68 USD -0.14

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $15.13 USD +0.02
Valeant Pharmaceuticals International Inc C$300.48 CAD +2.49
View Industry Companies

Industry Analysis


Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.2x
Price/Book 59.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at